Quantcast
Home > Quotes > BIIB
BIIB

Biogen Inc. Common Stock (BIIB) Quote & Summary Data

$240.29
*  
4.38
1.86%
Get BIIB Alerts
*Delayed - data as of Jun. 25, 2019  -  Find a broker to begin trading BIIB now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
250
Today's High / Low
$ 245.35 / $ 235.99
Share Volume
2,108,694
50 Day Avg. Daily Volume
1,886,437
Previous Close
$ 235.91
52 Week High / Low
$ 388.67 / $ 216.12
Market Cap
46,590,644,365
P/E Ratio
10.35
Forward P/E (1y)
7.98
Earnings Per Share (EPS)
$ 23.21
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.99

Intraday Chart

News for BIIB

Shares Traded

Share Volume:
2,108,694
50 Day Avg. Daily Volume:
1,886,437

P/E Ratio

P/E Ratio:
10.35
Forward P/E (1y):
7.98
Earnings Per Share (EPS):
$ 23.21

Trading Range

The current last sale of $240.29 is 11.18% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 245.35 $ 388.67
 Low: $ 235.99 $ 216.12

ETFs with BIIB as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
4.98% Invesco Dynamic Biotech & Genome ETF (PBE) +0.60 (1.16%)
4.93% VanEck Vectors Biotech ETF (BBH) -0.17 (-0.13%)
3.96% iShares Nasdaq Biotechnology Index Fund (IBB) -1.08 (-1.00%)
2.33% First Trust Health Care AlphaDEX (FXH) +2.73 (3.69%)
1.77% iShares Edge MSCI Multifactor USA ETF (LRGF) +1.45 (4.82%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas.  ... More ...  



Risk Grade

Where does BIIB fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 236.40
Open Date:
Jun. 25, 2019
Close Price:
$ 240.29
Close Date:
Jun. 25, 2019


Consensus Recommendation

Analyst Info